View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Declaration made pursuant to Article L. 233-8-II of the French Commerc...

Declaration made pursuant to Article L. 233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers InformationFebruary 11, 2026 Declaration made pursuant to Article L. 233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers Information relating to the total number of shares and voting rights comprising the share capital as of January 31, 2026 DateTotal number of shares1 comprising the share capitalTheoretical number of voting rights201/31/2026179 424 410179 42...

 PRESS RELEASE

Déclaration au titre de l’article L. 233-8 II du Code de Commerce et d...

Déclaration au titre de l’article L. 233-8 II du Code de Commerce et de l’article 223-16 du Règlement général de l’Autorité des marchés financiers Information11 février 2026 Déclaration au titre de l’article L. 233-8 II du Code de Commerce et de l’article 223-16 du Règlement général de l’Autorité des marchés financiers Information relative au nombre total de droits de vote et d’actions composant le capital social de la Société au 31 janvier 2026 DateNombre d’actions1 composant le capitalNombre théorique de droits de votes231/01/2026179 424 410179 424 410    * *         * SCOR, un réassu...

Novartis AG: 1 director

A director at Novartis AG sold 7,500 shares at 156.208USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Martijn Den Drijver
  • Martijn Den Drijver
 PRESS RELEASE

Novartis breaks ground on new global Biomedical Research center in San...

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel, SwitzerlandApproximately 466,000-square-foot site with AI-enabled discovery capabilities, expected to house about 1,000 employees Part of a USD 23 billion US investment to expand R&D and advanced manufacturing to reach more patients East Hanover, February 6, 2026 – Novartis today broke ground on a new, s...

Benoit Valleaux ... (+5)
  • Benoit Valleaux
  • Roland Pfaender
  • MBA
  • CFA
  • CCRA
Benoit Valleaux ... (+5)
  • Benoit Valleaux
  • Roland Pfaender
  • MBA
  • CFA
  • CCRA
Carole Braudeau
  • Carole Braudeau

Credit Morning 02/04/2026

Sappi: Very weak Q1 2025/26 and disappointing outlook, but liquidity remains satisfactory|ams OSRAM to sell its non-optical sensors for €570m|Santander announced strong 2025 results and the acquisition of a US bank for USD 12.2 bn.|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 04/02/2026

Sappi : T1 2025/26 très faible et perspectives décevantes, mais la liquidité tient|ams OSRAM va céder ses capteurs non optiques à Infineon pour 570 m EUR|Santander a annoncé de solides résultats 2025 et l’acquisition d’une banque US à 12.2 mds USD|

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch